Letters to the Editor

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Modus Outcomes, a division of THREAD, Lyon
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
Modus Outcomes, a division of THREAD, Lyon
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
AP-HP, Hôpital Saint Louis, Paris, France; University of Paris, and INSERM U944, Paris
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Haematologica Early view Dec 7, 2022 https://doi.org/10.3324/haematol.2022.281856